Concepedia

Douglas Reznick

DR

Statistics

Publications

2

Citations

106

H-Index

2

Active since

2022

Affiliations

Hospital Universitario 12 De Octubre(Current)

European Institute of Oncology

Gilead Sciences (United States)

Rocky Mountain Cancer Centers

Asklepios Fachkliniken München-Gauting

Douglas Reznick is an author at Hospital Universitario 12 De Octubre specializing in radiation oncology, immunology, and tumor immunity.

Top concepts

Publications per year

2022–2024

2

Publications

2

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Luis Paz‐Ares, Óscar Juan, Giannis Mountzios et al. · Journal of Clinical Oncology · 2024 · 91 citations · Full text

EVOKE-01: A phase 3 study of sacituzumab govitecan (SG) versus docetaxel in patients with non–small cell lung cancer (NSCLC) progressing on or after platinum-based chemotherapy and checkpoint inhibitors.

Marina Chiara Garassino, Douglas Reznick, Steven Y. Liu et al. · Journal of Clinical Oncology · 2022 · 15 citations

, , +23

1–2 of 2